1,682 Results

Current status of immune checkpoint inhibition in early stage NSCLC.

Immune checkpoint inhibition (ICI) immunotherapy has revolutionized the approach to metastatic non-small-cell lung cancer (NSCLC). In particular, antibodies blocking the inhibitory immune checkpoints programmed death...

Durvalumab in cancer medicine: a comprehensive review.

Introduction: The U.S. FDA has approved durvalumab for the treatment of advanced urothelial and non-small cell lung cancers. However, this immunotherapy agent is also being explored in other cancers.

Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available?

Summary: The present study reviews the current definition of advanced cSCC and discusses the new systemic approaches, including checkpoint inhibitors.

Systemic Immunotherapy for Advanced Cutaneous Squamous Cell Carcinoma.

Advanced (i.e., unresectable) cutaneous squamous cell carcinoma (cSCC) is a rare condition with a dismal prognosis. Although less than 5% of cSCC patients develop metastases or local recurrence after...

Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.

Cutaneous squamous cell carcinoma (cSCC) is the second most frequent type of malignancy in Caucasians worldwide. Several factors have been correlated with aggressiveness and likelihood of recurrence...

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.

Background: Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of ALK and ROS1 tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study, activity was seen in patients with ALK-positive...

Clinical Management of Adverse Events Associated with Lorlatinib.

Lorlatinib is a novel, highly potent, brain‐penetrant, third‐generation ALK/ROS1 tyrosine kinase inhibitor (TKI), which has broad‐spectrum potency against most known resistance mutations that can develop during treatment with...

Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.

Areas covered: The main mechanism of action, pharmacokinetics, clinical efficacy and safety of lorlatinib were introduced in this paper.

Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.

Rucaparib is a potent inhibitor of poly (ADP-ribose) polymerase (PARP) PARP1, PARP2 and PARP3, and to a lesser extent, PARP4, PARP10, PARP12, PARP15 and PARP16. Study 10 and ARIEL2 evaluated the use of rucaparib as...

How safe is rucaparib in ovarian cancer?

Areas covered: This review will discuss the mechanism of action, clinical efficacy data, and safety of rucaparib as presented from phase 1, 2, and 3 clinical trials.